ANI Pharmaceuticals announced the results of the NEW DAY clinical trial for ILUVIEN® (fluocinolone acetonide) in diabetic macular edema (DME) patients during the ASRS Annual Scientific Meeting. The ...
ANI Pharmaceuticals has disclosed the outcomes of its randomised NEW DAY trial, assessing Iluvien 0.19mg, in people with diabetic macular oedema (DME). The multicenter, prospective, masked, ...
Data highlight ILUVIEN’s advantages as the only therapy that consistently treats diabetic macular edema (DME) for up to 3 years ATLANTA, Oct. 01, 2019 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.
Please provide your email address to receive an email when new articles are posted on . The NEW DAY study did not meet its primary endpoint but showed good outcomes in secondary endpoints. A post hoc ...
ANI Pharmaceuticals (NASDAQ:ANIP) lost ~8% in the premarket on Wednesday after the company announced a failure in a clinical trial designed to test its FDA-approved Iluvien intravitreal implant ...
ATLANTA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned ...
ATLANTA, Sept. 29, 2014 -- Alimera Sciences, Inc. (ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic ...
Marbury Creative Group and Alimera Sciences are aiming to get diabetic macular edema (DME) treatment Iluvien on patients’ radars with the See Less to See More campaign. The nine-month effort, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results